Perceptive Advisors LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 29, 2026), Perceptive Advisors LLC reported 89 stock positions worth $5.0 billion. Its top holding was Praxis Precision Medicines I (PRAX) at 13.0% of the portfolio, followed by Celcuity (CELC, 7.1%) and Ascendis Pharma A/S (ASND, 6.9%). Compared with Q4 2025, it opened 18 new positions, sold out of 38, added to 23 and reduced 33. The biggest buy was Centessa Pharmaceuticals (CNTA, shares +80%) and the biggest sale an exit from Exact Sciences (EXAS).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001224962
- Portfolio Value
- $5.0B (Q1 2026)
- SEC Filing
- 0001012975-26-000499 ↗ filed May 29, 2026
Holdings Value
Holdings 89 stocks · $5.0B
| PRAX Praxis Precision Medicines I | 13.00% | 2,035,986 | $656.0M | Add +2.0% |
| CELC Celcuity Inc. | 7.07% | 3,127,200 | $356.9M | Reduce -1.0% |
| ASND Ascendis Pharma A/S | 6.94% | 1,531,421 | $350.3M | Add +41.6% |
| ROIV Roivant Sciences Ltd. | 4.55% | 8,285,461 | $229.5M | Add +3.8% |
| CNTA Centessa Pharmaceuticals Ltd. | 4.14% | 5,258,903 | $208.9M | Add +80.3% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.09% | 2,373,795 | $206.4M | Reduce -6.8% |
| SYRE Spyre Therapeutics Inc. | 3.78% | 3,783,225 | $190.8M | Add +23.3% |
| NUVL Nuvalent Inc. Class A | 3.21% | 1,580,505 | $161.9M | Reduce -5.1% |
| EWTX Edgewise Therapeutics Inc. | 2.76% | 4,423,974 | $139.4M | Reduce -0.8% |
| PTGX Protagonist Therapeutics Inc. | 2.57% | 1,230,879 | $129.7M | Reduce -8.8% |
| APGE Apogee Therapeutics Inc. | 2.57% | 1,540,384 | $129.7M | Reduce -33.9% |
| TVTX Travere Therapeutics Inc. | 2.44% | 4,142,551 | $123.1M | Reduce -3.2% |
| AMLX Amylyx Pharmaceuticals Inc. | 2.28% | 8,284,882 | $115.2M | No change |
| IMTX Immatics NV | 2.02% | 10,383,456 | $102.2M | No change |
| RLAY Relay Therapeutics Inc. | 1.92% | 9,751,141 | $97.0M | Add +412.3% |
| INBX Inhibrx Biosciences Inc. | 1.92% | 1,442,707 | $97.0M | Reduce -0.7% |
| MGTX Meiragtx Holdings PLC | 1.77% | 10,326,103 | $89.3M | No change |
| ZYME Zymeworks Inc. | 1.74% | 3,510,078 | $87.9M | Add +7.6% |
| SLDB Solid Biosciences Inc. | 1.70% | 11,906,646 | $85.7M | Add +0.6% |
| DYN Dyne Therapeutics Inc. | 1.68% | 4,668,839 | $84.6M | Add +34.2% |
| BCRX Biocryst Pharmaceuticals Inc. | 1.40% | 7,434,033 | $70.8M | Add +135.1% |
| ORKA Oruka Therapeutics Inc. | 1.36% | 1,395,501 | $68.4M | Reduce -5.5% |
| AORT Artivion Inc. | 1.19% | 1,637,290 | $60.0M | Reduce -4.9% |
| NRIX Nurix Therapeutics Inc. | 1.14% | 3,710,877 | $57.5M | Add +4.4% |
| NAUT Nautilus Biotechnology Inc. | 0.97% | 12,594,211 | $48.9M | No change |
| CTMX Cytomx Therapeutics Inc. | 0.94% | 10,098,824 | $47.5M | Add +4.3% |
| ANRO Alto Neuroscience Inc. | 0.90% | 2,009,893 | $45.2M | Add +12.6% |
| ENGN Engene Holdings Inc. | 0.79% | 5,827,506 | $39.7M | Reduce -0.7% |
| IMVT Immunovant Inc. | 0.79% | 1,597,383 | $39.7M | Reduce -19.9% |
| ISRG Intuitive Surgical Inc. | 0.78% | 85,419 | $39.4M | Reduce -2.8% |
| IONS Ionis Pharmaceuticals Inc. | 0.75% | 504,000 | $37.8M | New |
| DAWN Day One Biopharmaceuticals I | 0.75% | 1,755,799 | $37.6M | New |
| ABVX Abivax SA-ADR | 0.73% | 328,884 | $36.6M | Reduce -28.3% |
| CRVS Corvus Pharmaceuticals Inc. | 0.66% | 2,292,441 | $33.5M | Add +231.1% |
| RGEN Repligen Corp. | 0.66% | 280,541 | $33.1M | Reduce -11.1% |
| JAZZ Jazz Pharmaceuticals PLC | 0.64% | 170,000 | $32.1M | No change |
| DMRA Damora Therapeutics Inc. | 0.63% | 1,223,000 | $31.7M | New |
| XFOR X4 Pharmaceuticals Inc. | 0.55% | 6,737,648 | $27.8M | Add +6.7% |
| GH Guardant Health Inc. | 0.55% | 300,000 | $27.7M | Add +87.5% |
| DRUG Bright Minds Biosciences Inc. | 0.55% | 377,544 | $27.5M | Reduce -16.0% |
| IVVD Invivyd Inc. | 0.54% | 20,859,303 | $27.1M | Reduce -4.3% |
| SION Sionna Therapeutics Inc. | 0.52% | 658,439 | $26.4M | Reduce -44.2% |
| AXSM Axsome Therapeutics Inc. | 0.50% | 149,950 | $25.3M | Add +0.7% |
| RVMD Revolution Medicines Inc. | 0.50% | 258,600 | $25.1M | New |
| SABS Sab Biotherapeutics Inc. | 0.49% | 6,431,743 | $24.6M | Add +700.8% |
| BLTE Belite Bio Inc. - ADR | 0.48% | 151,979 | $24.2M | Reduce -63.3% |
| TENX Tenax Therapeutics Inc. | 0.46% | 1,447,782 | $23.2M | Add +229.7% |
| AXGN Axogen Inc. | 0.46% | 697,312 | $23.1M | Reduce -11.1% |
| VRDN Viridian Therapeutics Inc. | 0.45% | 1,170,829 | $22.9M | Reduce -61.5% |
| OBIO Orchestra Biomed Holdings Inc. | 0.42% | 5,037,906 | $21.4M | Reduce -1.7% |
| RAPP Rapport Therapeutics Inc. | 0.42% | 673,923 | $21.1M | No change |
| DBVT DBV Technologies SA-Spon ADR | 0.40% | 964,391 | $20.1M | New |
| LONA Leonabio Inc. | 0.38% | 1,859,322 | $19.1M | No change |
| AVR Anteris Technologies Global | 0.38% | 3,425,476 | $19.0M | Add +104.5% |
| STRO Sutro Biopharma Inc. | 0.35% | 715,307 | $17.8M | New |
| TNGX Tango Therapeutics Inc. | 0.34% | 808,153 | $16.9M | Add +57.5% |
| CTNM Contineum Therapeutics Inc. Class A | 0.33% | 1,255,592 | $16.4M | Reduce -14.3% |
| PALI Palisade Bio Inc. | 0.31% | 8,928,149 | $15.6M | Reduce -25.9% |
| OCS Oculis Holding AG | 0.26% | 493,827 | $13.1M | No change |
| IRTC Irhythm Holdings Inc. | 0.25% | 105,026 | $12.4M | Reduce -2.8% |
| ADGM Adagio Medical Holdings Inc. | 0.22% | 9,876,576 | $11.0M | No change |
| EVMN Evommune Inc. | 0.20% | 448,350 | $10.3M | New |
| PHAT Phathom Pharmaceuticals Inc. | 0.20% | 925,000 | $10.3M | New |
| NMRA Neumora Therapeutics Inc. | 0.20% | 5,104,097 | $10.0M | New |
| OMDA Omada Health Inc. | 0.20% | 786,330 | $9.9M | Reduce -67.2% |
| NBIX Neurocrine Biosciences Inc. | 0.17% | 65,050 | $8.6M | Reduce -80.3% |
| BBNX Beta Bionics Inc. | 0.17% | 842,944 | $8.4M | Add +39.8% |
| IRD Opus Genetics Inc. | 0.17% | 1,835,842 | $8.4M | Reduce -57.5% |
| BLLN Billiontoone Inc. Class A | 0.14% | 91,812 | $7.2M | Add +26.1% |
| TWST Twist Bioscience Corp. | 0.14% | 150,000 | $7.1M | New |
| SRZN Surrozen Inc. | 0.13% | 229,393 | $6.7M | New |
| AGMB Agomab Therapeutics NV | 0.12% | 600,000 | $6.3M | New |
| EOLS Evolus Inc. | 0.10% | 1,286,862 | $5.3M | New |
| COGT Cogent Biosciences Inc. | 0.09% | 121,082 | $4.7M | No change |
| ADMA Adma Biologics Inc. | 0.08% | 467,233 | $4.2M | Reduce -47.1% |
| IKT Inhibikase Therapeutics Inc. | 0.08% | 2,315,000 | $3.9M | Reduce -57.3% |
| CBIO Crescent Biopharma Inc. | 0.08% | 206,942 | $3.8M | Reduce -54.4% |
| APLS Apellis Pharmaceuticals Inc. | 0.06% | 80,956 | $3.3M | New |
| OM Outset Medical Inc. | 0.06% | 833,333 | $3.2M | No change |
| EDSA Edesa Biotech Inc. | 0.06% | 563,239 | $2.9M | New |
| ADPT Adaptive Biotechnologies | 0.04% | 152,500 | $2.1M | New |
| AVTX Avalo Therapeutics Inc. | 0.04% | 139,667 | $2.1M | No change |
| CNTB Connect Biopharma Holdings L | 0.04% | 792,696 | $2.1M | No change |
| CORT Corcept Therapeutics Inc. | 0.04% | 50,000 | $2.0M | New |
| MDLN Medline Inc. Class A | 0.02% | 28,000 | $1.2M | No change |
| PTN Palatin Technologies Inc. | 0.02% | 61,945 | $1.1M | Reduce -11.5% |
| CPIX Cumberland Pharmaceuticals | 0.01% | 196,978 | $640K | Reduce -42.3% |
| XGN Exagen Inc. | 0.01% | 114,893 | $345K | New |
| ENSC Ensysce Biosciences Inc. | 0.00% | 86,666 | $47K | No change |
Options reported separately and not counted above: MRNA puts ($50.8M), OCUL calls ($4.2M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $16.3M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| CELCUITY INC (CELC 2.75 08/01/31) | NOTE 2.750% 8/0 · principal | 6,500,000 | $15.9M | No change |
| RVMDW Revolution Medicines Inc.-28 | *W EXP 12/17/202 | 250,000 | $448K | No change |
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 166,666 | $3K | No change |
Total filed on the 13F, all lines: $5.1B.
Portfolio Sells Q4 2025 → Q1 2026
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −2.24 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −1.76 |
| BSX Boston Scientific Corp. | Sold out | 0.00% | −1.71 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −1.67 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −1.56 |
| VRDN Viridian Therapeutics Inc. | Reduce -61.5% | 0.45% | −1.29 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -6.8% | 4.09% | −0.92 |
| DHR Danaher Corp. | Sold out | 0.00% | −0.84 |
| BLTE Belite Bio Inc. - ADR | Reduce -63.3% | 0.48% | −0.74 |
| NBIX Neurocrine Biosciences Inc. | Reduce -80.3% | 0.17% | −0.69 |
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −0.67 |
| APGE Apogee Therapeutics Inc. | Reduce -33.9% | 2.57% | −0.66 |
| IRON Disc Medicine Inc. | Sold out | 0.00% | −0.66 |
| PEN Penumbra Inc. | Sold out | 0.00% | −0.63 |
| TVTX Travere Therapeutics Inc. | Reduce -3.2% | 2.44% | −0.56 |
| CAI Caris Life Sciences Inc. | Sold out | 0.00% | −0.56 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| PVLA Palvella Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| OMDA Omada Health Inc. | Reduce -67.2% | 0.20% | −0.50 |
| IVVD Invivyd Inc. | Reduce -4.3% | 0.54% | −0.45 |
| KOD Kodiak Sciences Inc. | Sold out | 0.00% | −0.44 |
| ABVX Abivax SA-ADR | Reduce -28.3% | 0.73% | −0.41 |
| BIIB Biogen Inc. | Sold out | 0.00% | −0.40 |
| ALDX Aldeyra Therapeutics Inc. | Sold out | 0.00% | −0.40 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.38 |
| GRAL Grail Inc. | Sold out | 0.00% | −0.37 |
| SION Sionna Therapeutics Inc. | Reduce -44.2% | 0.52% | −0.37 |
| CVS CVS Health Corp. | Sold out | 0.00% | −0.32 |
| RGEN Repligen Corp. | Reduce -11.1% | 0.66% | −0.29 |
| GKOS Glaukos Corp. | Sold out | 0.00% | −0.29 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −0.28 |
| SVRA Savara Inc. | Sold out | 0.00% | −0.27 |
| AORT Artivion Inc. | Reduce -4.9% | 1.19% | −0.25 |
| SEPN Septerna Inc. | Sold out | 0.00% | −0.22 |
| ADMA Adma Biologics Inc. | Reduce -47.1% | 0.08% | −0.21 |
| PALI Palisade Bio Inc. | Reduce -25.9% | 0.31% | −0.21 |
| ENGN Engene Holdings Inc. | Reduce -0.7% | 0.79% | −0.19 |
| INBX Inhibrx Biosciences Inc. | Reduce -0.7% | 1.92% | −0.19 |
| GOSS Gossamer Bio Inc. | Sold out | 0.00% | −0.18 |
| MPLT Maplight Therapeutics Inc. | Sold out | 0.00% | −0.18 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −0.17 |
| IMVT Immunovant Inc. | Reduce -19.9% | 0.79% | −0.15 |
| KMTS Kestra Medical Technologies | Sold out | 0.00% | −0.14 |
| ISRG Intuitive Surgical Inc. | Reduce -2.8% | 0.78% | −0.13 |
| IKT Inhibikase Therapeutics Inc. | Reduce -57.3% | 0.08% | −0.13 |
| IRTC Irhythm Holdings Inc. | Reduce -2.8% | 0.25% | −0.11 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| PEPG Pepgen Inc. | Sold out | 0.00% | −0.10 |
| DRUG Bright Minds Biosciences Inc. | Reduce -16.0% | 0.55% | −0.10 |
| AQST Aquestive Therapeutics Inc. | Sold out | 0.00% | −0.09 |
Portfolio Buys Q4 2025 → Q1 2026
| CNTA Centessa Pharmaceuticals Ltd. | Add +80.3% | 4.14% | +2.80 |
| ASND Ascendis Pharma A/S | Add +41.6% | 6.94% | +2.71 |
| PRAX Praxis Precision Medicines I | Add +2.0% | 13.00% | +2.19 |
| SYRE Spyre Therapeutics Inc. | Add +23.3% | 3.78% | +1.93 |
| RLAY Relay Therapeutics Inc. | Add +412.3% | 1.92% | +1.63 |
| ROIV Roivant Sciences Ltd. | Add +3.8% | 4.55% | +1.37 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +135.1% | 1.40% | +0.95 |
| IONS Ionis Pharmaceuticals Inc. | New | 0.75% | +0.75 |
| DAWN Day One Biopharmaceuticals I | New | 0.75% | +0.75 |
| DMRA Damora Therapeutics Inc. | New | 0.63% | +0.63 |
| CRVS Corvus Pharmaceuticals Inc. | Add +231.1% | 0.66% | +0.57 |
| RVMD Revolution Medicines Inc. | New | 0.50% | +0.50 |
| SLDB Solid Biosciences Inc. | Add +0.6% | 1.70% | +0.47 |
| SABS Sab Biotherapeutics Inc. | Add +700.8% | 0.49% | +0.43 |
| DYN Dyne Therapeutics Inc. | Add +34.2% | 1.68% | +0.43 |
| DBVT DBV Technologies SA-Spon ADR | New | 0.40% | +0.40 |
| TENX Tenax Therapeutics Inc. | Add +229.7% | 0.46% | +0.36 |
| STRO Sutro Biopharma Inc. | New | 0.35% | +0.35 |
| ANRO Alto Neuroscience Inc. | Add +12.6% | 0.90% | +0.31 |
| TNGX Tango Therapeutics Inc. | Add +57.5% | 0.34% | +0.25 |
| GH Guardant Health Inc. | Add +87.5% | 0.55% | +0.25 |
| AVR Anteris Technologies Global | Add +104.5% | 0.38% | +0.22 |
| EVMN Evommune Inc. | New | 0.20% | +0.20 |
| PHAT Phathom Pharmaceuticals Inc. | New | 0.20% | +0.20 |
| NMRA Neumora Therapeutics Inc. | New | 0.20% | +0.20 |
| CTMX Cytomx Therapeutics Inc. | Add +4.3% | 0.94% | +0.18 |
| ZYME Zymeworks Inc. | Add +7.6% | 1.74% | +0.16 |
| TWST Twist Bioscience Corp. | New | 0.14% | +0.14 |
| SRZN Surrozen Inc. | New | 0.13% | +0.13 |
| AGMB Agomab Therapeutics NV | New | 0.12% | +0.12 |
| EOLS Evolus Inc. | New | 0.10% | +0.10 |
| XFOR X4 Pharmaceuticals Inc. | Add +6.7% | 0.55% | +0.09 |
| APLS Apellis Pharmaceuticals Inc. | New | 0.06% | +0.06 |
| EDSA Edesa Biotech Inc. | New | 0.06% | +0.06 |
| ADPT Adaptive Biotechnologies | New | 0.04% | +0.04 |
| CORT Corcept Therapeutics Inc. | New | 0.04% | +0.04 |
| BLLN Billiontoone Inc. Class A | Add +26.1% | 0.14% | +0.03 |
| XGN Exagen Inc. | New | 0.01% | +0.01 |
| AXSM Axsome Therapeutics Inc. | Add +0.7% | 0.50% | +0.00 |
| NRIX Nurix Therapeutics Inc. | Add +4.4% | 1.14% | −0.10 |
| BBNX Beta Bionics Inc. | Add +39.8% | 0.17% | −0.17 |
Options Activity Q4 2025 → Q1 2026
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 1,100,000 | $134.1Mbefore exit |
| MRNA Moderna Inc. | put | New | 1,000,000 | $50.8M |
| CAPR Capricor Therapeutics Inc. | call | Sold out | 242,100 | $7.0Mbefore exit |
| BHVN Biohaven Ltd. | call | Sold out | 500,000 | $5.6Mbefore exit |
| TECX Tectonic Therapeutic Inc. | call | Sold out | 250,000 | $5.2Mbefore exit |
| OCUL Ocular Therapeutix Inc. | call | New | 500,000 | $4.2M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $6.4B | PRAX, SYRE, CELC, ASND, RYTM |
| Q1 2026Amended | 89 | $5.0B | PRAX, CELC, ASND, ROIV, CNTA |
| Q4 2025 | 109 | $5.4B | PRAX, CELC, RYTM, ASND, APGE |
| Q3 2025 | 88 | $3.4B | RYTM, ASND, ACLX, CELC, NUVL |
| Q2 2025 | 80 | $2.7B | VRNA, ASND, ACLX, RYTM, NUVL |
| Q1 2025Amended | 84 | $2.8B | VRNA, ACLX, FOLD, EWTX, RYTM |
| Q4 2024 | 95 | $3.6B | VRNA, ACLX, FOLD, RYTM, NUVL |
| Q3 2024 | 99 | $4.7B | ACLX, NUVL, FOLD, IOVA, PCVX |
| Q2 2024Amended | 104 | $4.1B | CERE, FOLD, ACLX, IOVA, NUVL |
| Q1 2024Amended | 102 | $5.7B | CERE, FOLD, IOVA, ACLX, NUVL |